🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 1 día
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/07/2019 8,29 8,70 8,23 8,67 +3,83% 5,67% 98.800
23/07/2019 8,46 8,50 8,22 8,35 -1,42% 3,29% 58.900
22/07/2019 8,17 8,49 8,14 8,47 +3,67% 4,28% 116.800
19/07/2019 8,49 8,57 8,13 8,17 -4,22% 5,18% 64.600
18/07/2019 8,45 8,60 8,40 8,53 +0,95% 2,37% 47.800
17/07/2019 8,43 8,71 8,39 8,45 +0,12% 3,80% 81.900
16/07/2019 8,31 8,68 8,19 8,44 +1,32% 5,90% 75.700
15/07/2019 8,21 8,44 7,78 8,33 +2,84% 8,04% 176.400
12/07/2019 8,46 8,67 7,91 8,10 -4,93% 8,98% 180.800
11/07/2019 8,52 8,64 8,31 8,52 +0,24% 3,87% 94.700
10/07/2019 8,70 8,80 8,24 8,50 -1,05% 6,44% 127.400
09/07/2019 8,45 8,70 8,34 8,59 +0,35% 4,26% 46.400
08/07/2019 8,60 8,62 8,39 8,56 -1,61% 2,72% 70.100
05/07/2019 8,29 8,93 8,29 8,70 +4,44% 7,72% 147.100
03/07/2019 8,17 8,43 8,10 8,33 +1,96% 4,04% 45.800
02/07/2019 7,95 8,49 7,81 8,17 +2,90% 8,62% 135.800
01/07/2019 8,17 8,22 7,78 7,94 -0,13% 5,37% 220.600
28/06/2019 7,69 8,04 7,60 7,95 +2,85% 5,72% 1.008.200
27/06/2019 7,49 7,73 7,31 7,73 +6,04% 5,61% 151.700
26/06/2019 9,20 9,20 7,15 7,29 -23,02% 22,28% 403.000
25/06/2019 9,40 9,70 9,06 9,47 +2,16% 6,81% 161.700
24/06/2019 9,46 9,77 9,18 9,27 -1,80% 6,29% 195.300
21/06/2019 9,20 9,92 9,11 9,44 +1,83% 8,80% 201.200
20/06/2019 9,35 9,60 9,14 9,27 -0,11% 4,92% 179.100
19/06/2019 9,23 9,36 9,00 9,28 -0,11% 3,90% 93.900
18/06/2019 9,12 9,47 9,06 9,29 +2,65% 4,50% 177.000
17/06/2019 8,31 9,20 8,28 9,05 +9,30% 11,07% 1.518.300
14/06/2019 8,56 8,81 8,12 8,28 -3,04% 8,06% 484.100
13/06/2019 8,32 8,63 8,17 8,54 +3,02% 5,53% 129.000
12/06/2019 7,91 8,53 7,82 8,29 +6,42% 8,95% 239.500